Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by Summit Trail Advisors LLC

Summit Trail Advisors LLC grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 31.8% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 4,533 shares of the medical equipment provider’s stock after purchasing an additional 1,095 shares during the period. Summit Trail Advisors LLC’s holdings in Zimmer Biomet were worth $480,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Geode Capital Management LLC increased its holdings in Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock valued at $524,942,000 after acquiring an additional 125,852 shares in the last quarter. M&T Bank Corp increased its stake in shares of Zimmer Biomet by 48.4% during the 3rd quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after purchasing an additional 8,709 shares in the last quarter. Peddock Capital Advisors LLC acquired a new position in shares of Zimmer Biomet during the 4th quarter worth approximately $654,000. National Pension Service lifted its stake in Zimmer Biomet by 3.8% in the 3rd quarter. National Pension Service now owns 369,547 shares of the medical equipment provider’s stock valued at $39,893,000 after buying an additional 13,612 shares in the last quarter. Finally, River Global Investors LLP grew its holdings in Zimmer Biomet by 31.3% during the 3rd quarter. River Global Investors LLP now owns 21,084 shares of the medical equipment provider’s stock valued at $2,276,000 after buying an additional 5,030 shares during the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Stock Down 1.3 %

Shares of NYSE:ZBH opened at $99.13 on Wednesday. The stock has a 50-day simple moving average of $107.14 and a 200-day simple moving average of $107.99. The stock has a market capitalization of $19.73 billion, a P/E ratio of 22.28, a PEG ratio of 1.83 and a beta of 1.02. Zimmer Biomet Holdings, Inc. has a 1 year low of $98.94 and a 1 year high of $133.90. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.70 and a current ratio of 1.91.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same quarter in the prior year, the company earned $2.20 earnings per share. Equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.25 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were given a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.97%. The ex-dividend date of this dividend was Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Wall Street Analyst Weigh In

ZBH has been the subject of a number of analyst reports. Barclays cut their price target on Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday. JMP Securities reissued a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research note on Friday, February 7th. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Raymond James cut their price objective on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Finally, Royal Bank of Canada decreased their target price on shares of Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $124.15.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.